Literature DB >> 33640716

Neurokinin-1 receptor signaling induces a pro-inflammatory transcriptomic profile in CD16+ monocytes.

Vasiliki Pappa1, Sergei Spitsin1, Peter J Gaskill2, Steven D Douglas3.   

Abstract

Neurokinin-1 receptor (NK1R) signaling can be immunomodulatory and it can lead to preferential transmigration of CD14+CD16+ monocytes across the blood brain barrier, potentially promoting the development of inflammatory neurological diseases, such as neuroHIV. To evaluate how NK1R signaling alters monocyte biology, RNA sequencing was used to define NK1R-mediated transcriptional changes in different monocyte subsets. The data show that NK1R activation induces a greater number of changes in CD14+CD16+ monocytes (152 differentially expressed genes), than in CD14+CD16- monocytes (36 genes), including increases in the expression of NF-κB and components of the NLRP3 inflammasome pathway. These results suggest that NK1R may alter the inflammatory state of CD14+CD16+ monocytes, influencing the development of neuroinflammation.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD16; Monocyte subsets; Neurokinin-1 receptor; RNA sequencing; Substance P

Mesh:

Substances:

Year:  2021        PMID: 33640716      PMCID: PMC8988161          DOI: 10.1016/j.jneuroim.2021.577524

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  21 in total

1.  Substance P and Antagonists of the Neurokinin-1 Receptor in Neuroinflammation Associated with Infectious and Neurodegenerative Diseases of the Central Nervous System.

Authors:  Alejandra N Martinez; Mario T Philipp
Journal:  J Neurol Neuromedicine       Date:  2016

2.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

3.  JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals.

Authors:  Dionna W Williams; Kathryn Anastos; Susan Morgello; Joan W Berman
Journal:  J Leukoc Biol       Date:  2014-11-24       Impact factor: 4.962

4.  mTORC1-Induced HK1-Dependent Glycolysis Regulates NLRP3 Inflammasome Activation.

Authors:  Jong-Seok Moon; Shu Hisata; Mi-Ae Park; Gina M DeNicola; Stefan W Ryter; Kiichi Nakahira; Augustine M K Choi
Journal:  Cell Rep       Date:  2015-06-25       Impact factor: 9.423

5.  Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor.

Authors:  Jian-Ping Lai; Saien Lai; Florin Tuluc; Morris F Tansky; Laurie E Kilpatrick; Susan E Leeman; Steven D Douglas
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-19       Impact factor: 11.205

6.  Production of interleukin-1 by microglia in response to substance P: role for a non-classical NK-1 receptor.

Authors:  F C Martin; P A Anton; J A Gornbein; F Shanahan; J E Merrill
Journal:  J Neuroimmunol       Date:  1993-01       Impact factor: 3.478

7.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.

Authors:  Michael I Love; Wolfgang Huber; Simon Anders
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

8.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

9.  Glycolysis Is Required for LPS-Induced Activation and Adhesion of Human CD14+CD16- Monocytes.

Authors:  Man K S Lee; Annas Al-Sharea; Waled A Shihata; Camilla Bertuzzo Veiga; Olivia D Cooney; Andrew J Fleetwood; Michelle C Flynn; Ellen Claeson; Clovis S Palmer; Graeme I Lancaster; Darren C Henstridge; John A Hamilton; Andrew J Murphy
Journal:  Front Immunol       Date:  2019-09-06       Impact factor: 7.561

10.  The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1β-dependent manner in macrophages.

Authors:  Orla M Finucane; Jamie Sugrue; Ana Rubio-Araiz; Marie-Victoire Guillot-Sestier; Marina A Lynch
Journal:  Sci Rep       Date:  2019-03-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.